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ABSTRACT 
Uncoupling protein 1 (UCP1) is a classical feature of brown adipocytes and 
understanding its regulatory mechanism will help in the development of a pharmacological 
approach for obesity and associated metabolic diseases. The epigenetic regulation of UCP1 in 
brown adipocytes is not completely understood. Our study is focused on histone deacetylases 
(HDACs), which are set of enzymes that bring about changes in gene expression pattern by 
changing the histone acetylation status. Our data suggest that inhibition of Class-I HDACs can 
increase the expression of UCP1 in brown and white adipocytes; whereas inhibition of Class-II 
HDACs can decrease the UCP1 expression in brown adipocytes. Thus, by pharmacologically 
targeting specific HDAC enzymes, it might be possible to modulate UCP1 expression and 
thermogenic function in brown and white adipocytes. This will help burning excessive energy in 
the form of heat and in turn promote reduction of body weight, alleviate obesity and associated 
metabolic diseases. 
INDEX WORDS: Uncoupling protein 1, Brown fat, Epigenetics, Histone deacetylase (HDAC),  
HDAC inhibitors, Obesity 
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1     INTRODUCTION  
Obesity is a medical condition which is characterized by excessive storage and 
accumulation of body fat. This accumulation of adiposity causes several additional metabolic 
disorders such as: diabetes, hypertension, dyslipidemia, fatty liver (non-alcoholic) syndrome and 
cardio-vascular diseases. The co-morbidities associated with obesity pose a severe threat to 
human life and quality of living. Thus, a treatment to obesity will not only promote weight loss 
but also improve the quality of human life.  
 
Adipose tissue has a fundamental role in both distribution and storage of energy and thus 
contributes equally to energy homeostasis and metabolism. Adipose tissue is broadly classified 
into two main types: white adipose tissue (WAT), which preserves the energy in the form of tri-
glycerides and brown adipose tissue (BAT), which wastes energy in the form of heat using un-
coupling protein 1 (UCP1). This process is called non-shivering thermogenesis and is driven by 
uncoupling oxidative phosphorylation in mitochondria1. UCP1 can also be induced in white fat. 
Such cells that express UCP1 in WAT are called beige cells2. As energy is dissipated by this 
special protein-UCP1 in the form of heat, it is of special interest and target for scientists to study 
its mechanisms to treat obesity and promote weight loss. UCP1 expression can be up-regulated 
using stimulatory responses such as prolonged cold exposure and stimulation by adrenergic 
receptors3. Recent studies have shed insight into the molecular mechanisms behind UCP1 
induction in WAT. One such study have stated how positive regulators like peroxisome 
proliferator-activated receptor gamma (PPARγ), Peroxisome proliferator-activated receptor 
gamma co-activator 1-alpha (PGC1α) and Peroxisome proliferator-activated receptor gamma co-
activator 1-beta (PGC1β), PR domain containing 16 (PRDM16), and negative regulators like 
2 
Retinoblastoma (Rb), receptor interacting protein 140 (RIP140) contributes towards 
transcriptional regulation of UCP112.   
 
PGC1α and PGC1β are two transcriptional co-activators which are closely related to each 
other and they play a vital role in up-regulation of fatty acid oxidation genes. They are also 
known to increase mitochondrial biogenesis18. PRDM16 is a classical gene in brown fat fate 
determination, which increases the expression of PGC1α, and interacts with important regulators 
of brown fat function, including PGC1α, PGC1β, PPARα and PPARγ, thereby promoting brown 
adipocyte phenotype and thermogenic function24. Higher levels of PGC1α and PGC1β mRNA 
expression are necessary for expression of UCP1 and are inversely correlated with obesity18. 
Recent studies also state that the interaction between PPARγ and PGC1α greatly augments the 
activity of PPARγ in up-regulation of UCP1 expression. This evidence throws light on the 
importance of PGC1α and PGC1β in regulation of brown fat phenotype, as well as UCP1 
expression.  
 
On the other hand, it is fairly necessary to understand the repressive mechanisms of 
UCP1. The retinoblastoma protein (Rb) belongs to retinoblastoma gene family, is one of the 
classical repressors of UCP1 expression. Rb has an ability to switch between the WAT and BAT 
fate and is involved in cell cycle and differentiation42. Rb protein phosphorylation or any other 
functional inactivation of Rb protein has been correlated with induction of brown fat fate and 
higher expression of UCP1 expression in WAT16. These studies demonstrate a repressive role of 
Rb1 in UCP1 expression. Interactions between Rb and FOXC2 are postulated to be involved in a 
signaling cascade that increases the level of a UCP1 regulatory protein, Protein Kinase A-RIα17.  
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Great effort has been devoted to unravel the regulation of brown fat function by these 
signaling pathways. The epigenetic regulation and mechanisms of UCP1 expression, however, 
are largely unexplored. Through this study, we mainly addressed the questions behind the 
epigenetic control mechanisms of UCP1. Understanding these mechanisms will help in 
promoting brown fat function and induction of brown fat mechanisms in white adipocytes to 
promote weight loss.  
 
Epigenetics is the study of heritable modifications in the patterns of gene expression 
caused by mechanisms other than alterations in the actual DNA sequence itself 4. This is either 
due to DNA methylation or histone modifications including acetylation, ubiquitination, 
methylation, ADP-ribosylation, phosphorylation and sumoylation. Epigenetic control of obesity 
has been previously reported in the literature. Recent research has demonstrated that histone 3 
lysine 9 [H3-K9] specific demethylase Jhdm2a, plays an important role in obesity by controlling 
the expression of PPARα and UCP115. In addition, the pattern of CpG island methylation of the 
enhancer regions of UCP1 is found to be specific to the tissues and thus alters the expression 
pattern of the UCP1 protein in different tissues6. Furthermore, nuclear hormone co-repressor, 
RIP 140 is involved in increasing the assembly of histone methyltransferase on UCP1 enhancer 
regions. This specifically methylates the CpG islands of the enhancer regions of UCP1 and its 
co-activators, leading to UCP1 suppression7. All of these validate the significance of epigenetics 
in the control of adipose tissue metabolism and function. The role of HDAC modulation of 
UCP1 gene expression in brown adipocytes, however, remains unidentified.  
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HDACs are a set of enzymes, which acts on histones to remove acetyl groups from them. 
This modification, enhances the ability of histones to wrap around the DNA more tightly. 
Inhibiting HDAC causes up-regulation whereas activating HDAC causes down-regulation of 
genes.  HDACs are divided into four different super families: Class I to IV. Class I is comprised 
of HDAC- 1, 2, 3 and 8, whereas Class II-a includes HDAC-4, 5, 7, and 9, and Class II-b 
includes HDAC 6 and 10. Class IV includes HDAC 11. HDAC III includes the sirtuins, which 
uses NAD+ as cofactor and hence different from the rest of HDACs 8, 9. In the current project, we 
mainly focused on Class I and II HDACs. 
 
  Our preliminary data indicate that TSA (pan HDAC inhibitor) down-regulates UCP1 
expression. In contrary, a recent study has revealed that injection of Class I HDAC inhibitors in 
mice increases mitochondrial activity, ameliorates obesity and insulin resistance in skeletal 
muscles and increases UCP1 expression in brown adipose tissue10. On one hand, this provides 
confirmation that chromatin modification using pharmacological agents could play an important 
role in treatment of obesity. On the other hand, these seemingly contradictory effects of the pan-
HDAC inhibitor TSA and the class I HDAC inhibitor on oxidative pathway and UCP1 
expression may be due to the action of different classes of HDACs in the body. The precise 
mechanism by which different classes of HDACs regulate UCP1 expression is not clear. Thus, 
we studied the contrasting roles of this epigenetic mechanism in UCP1 expression in order to 
provide more insight towards formulation of new therapeutics for obesity and diabetes. 
 
 Therefore, in this project, we analyzed the roles of different classes of HDACs in the 
regulation of brown adipocyte UCP1 expression and function. We hypothesize that there are two 
5 
different regulatory mechanisms in UCP1 expression by HDACs. Inhibiting the Class I HDACs 
potentially up-regulated UCP1 expression whereas inhibiting the Class II HDACs down-
regulated the UCP1 expression.  We also studied the mechanisms underlying the differential 
regulation of brown adipocyte UCP1 expression and function by the different HDACs. 
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2. AIM AND HYPOTHESIS 
The overall aim of this study is to identify the mechanisms of epigenetic regulation in 
UCP1 expression by histone acetylation. 
 
2.1 Specific aims 
1. To evaluate the effect of Class-I HDAC inhibition on UCP1 regulation and brown fat 
function  
2. To study the role of Class-II HDAC inhibition on UCP1 expression and brown fat 
function 
 
2.2 Hypothesis 
We hypothesize that there are two different regulatory mechanisms of UCP1 expression 
by HDACs. Inhibition of the Class I HDACs can potentially up-regulate UCP1 expression and 
on the other hand inhibition of the Class II HDACs can down-regulate the UCP1 expression. 
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3    MATERIALS AND METHODS 
 
3.1 Chemical reagents 
All HDAC inhibitors, MS-275, MC 1568 and TSA (Trichostatin A) was obtained from 
selleckchem.com. The working concentrations of these HDAC inhibitors are: TSA- 500nM, MS-
275- 5µM, MC-1568- 30µM 10. 
 
3.2 Cell culture 
Brown adipocytes cell lines, HIB1B and BAT1 and white adipocyte cell line 3T3-L1 
were used. HIB1B cells were grown in high glucose Dulbecco's Modified Eagle’s Medium 
(DMEM) along with 10% Fetal Bovine Serum (FBS) and 1% Penicillin Streptomycin (PS) 
antibiotics at 37ºC in a humidified atmosphere of 5% CO2. 3T3-L1 cells were grown in high 
glucose DMEM along with 10% New Born Calf Serum and 1% PS antibiotics at 37ºC in a 
humidified atmosphere of 5% CO2. BAT1 cells were grown in DMEM/F-12 nutrient mixture 
along with 10% FBS and 1% PS antibiotics at 37ºC in a humidified atmosphere of 5% CO2. 
Undifferentiated HIB1B cells and differentiated HIB1B and BAT1 adipocytes were then pre-
treated with HDAC inhibitors for 30 minutes followed by norepinephrine (HIB1B) or 
isoproterenol (BAT1) stimulation for 4 and 3 hours respectively for induction of UCP1 
expression. Differentiated 3T3-L1 cells were treated with MS-275 for various time and then cells 
were harvested for RNA expression measurement. 
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3.3 Differentiation of pre-adipocyte cell lines  
3.3.1 3T3L1 adipocyte differentiation 
The 3T3L1 cells were grown until post confluent in DMEM high glucose medium, 10% 
calf serum and 1% PS. After post confluence 2-3 days, the differentiation was induced using the 
mixture containing: DMEM medium, 10% FBS, 1% PS, insulin (800nM), isobutyl-1-
methylxanthine (500µM) and dexamathason (1µM) for 2 days. After the differentiation, the cells 
were maintained in 800nM insulin medium with DMEM, 10% FBS and 1% PS for another 2- 4 
days. After complete differentiation of cells, they were grown in regular medium with DMEM, 
10% FBS and 1% PS for additional 4- 8 days. 
 
3.3.2 HIB1B brown adipocyte differentiation 
The HIB1B cells were allowed to grow confluent and the differentiation medium 
containing DMEM medium, 10% FBS, 1% PS, insulin (800nM), isobutyl-1-methylxanthine 
(500µM) and dexamethasone (1µM), indomethacin (100µM), thyroid hormone (T3) (1nM) were 
added to induce differentiation of cells for 3 days. Followed by this, the medium were changed to 
maintenance medium containing DMEM medium, 10% FBS, 1% PS, insulin (800nM) and T3 
(1nM) until 8 days.  
 
3.3.3 BAT1 differentiation  
The BAT1 cells were allowed to grow until they are 90% confluent. These cells were 
then be induced for differentiation for 48 hours using the differentiation mix containing: 
DMEM/F-12 medium, 10% FBS, 1% PS, insulin (20nM), isobutyl-1-methylxanthine (500µM) 
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and dexamethasone (0.5µM), indomethacin (125µM), T3 (1nM). The cells were then switched to 
maintenance medium containing DMEM/F-12 medium, 10% FBS, 1% PS, insulin (20nM) and 
T3 (1nM). The cells differentiated completely in another 5-6 days. 
 
3.4 RNA Isolation and quantitative RT-PCR  
Total RNA were isolated and extracted from cells using Tri-Reagent. The quantification 
of messenger RNAs of the gene of interest were done using real time-PCR using TaqMan One-
step RT-PCR master mix (Applied BioSystems, Foster City, CA) and Stratagene Mx300P system 
(Stratagene, La Jolla, CA). The concentration of the mRNA used were between 8ng to 50ng and 
the mRNA quantitation were normalized by the corresponding cyclophilin mRNA measurement. 
TaqMan primer/probes for all genes were bought from Applied Biosystems15. The primer 
sequence for all the genes are provided in Table1. 
 
3.5 siRNA Knockdown  
For knockdown of gene expression in HIB1B cells using siRNA, Reverse Transfection 
procedure were followed. In the first step, RNAi duplex-Lipofectamine™, RNAiMAX 
complexes were prepared. For this, 6 pmol RNAi duplex was diluted in 100 µl Opti-MEM® I 
Medium containing no serum and gently mixed. 1.5 µl of Lipofectamine™ RNAiMAX were 
added and the obtained mix was incubated for 10-20 minutes at RT. Next, the cells which were 
allowed to grow to 90% confluence were trypsinized and these cells were diluted in the growth 
medium without antibiotics. The concentration of the cells were optimized to 1x 105 cells/well. 
This will ensure that 500 µl has the appropriate amount of cells to provide 30-50% confluence 
after plating. Then the mixture containing RNAi duplex - Lipofectamine™ RNAiMAX 
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complexes and cells were plated. The cells were incubated for 24-72 hours at 37ºC in a CO2 
incubator. They were then be pre-treated with HDAC inhibitors for 30 minutes followed by 4 
hours of adrenergic stimulation (nor-epinephrine treatment). Then the gene expression was 
analyzed. 
 
For siRNA knock down of gene expression in BAT-1 cells, Electroporation technique 
were used. The cells obtained from Day 4 differentiation were trypsinized and diluted to the 
concentration of 3x106 cells/plate in the medium without antibiotics. Based on manufacture’s 
instruction from Lonza (Amaxa Cell Line Nuclefector Kit L) 400µL of Nucleofector solution L 
was added. After this, 20pmol of siRNA was added per sample. This mixture will then be 
electroporated using Amaxa biosystems. Immediately after electroporation, the mixture was 
transferred to a fresh 50 ml tube and mixed with 500µl of maintenance medium/well and plated. 
The cells were incubated at 37ºC in a CO2 incubator for additional 2 days. The cells were then 
be pre-treated with HDAC inhibitors for 30 minutes followed by 3 hours of adrenergic 
stimulation (isoproterenol treatment). Then the gene expression was analyzed. 
 
3.6 Chromatin Immuno-Precipitation assay  
At the 6th day of differentiation, the cells were first with HDAC inhibitors for 30 minutes 
and followed by adrenergic stimulation. After treatment, the cells were fixed with 1% of 
formaldehyde. Protease inhibitors such as: 1 mM phenylmethylsulfonyl fluoride (PMSF) and 
1µg/ml pepstatin A are added to ice cold PBS and this was used to wash the fixed cells.  The 
cells were scrapped and collected in a conical tube. After a brief centrifugation, the pellet was 
suspended in SDS lysis buffer containing 1% SDS, 10mM EDTA and 50mM Tris. The cell 
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lysate was sonicated to obtain genomic DNA fragment of length 200–1000 bp. These lysate were 
then centrifuged, and the supernatant of the sample was collected. Followed by this, the 
supernatant was immuno-precipitated with the antibodies against acetyl histone 3 or antibodies 
against specific lysine residues on H3. The immuno-complex which underwent immune-
precipitation were washed and reverse cross-linked using NaCl. Followed by this the samples are 
digested with protease K. The DNA was isolated using phenol/chloroform extraction method. 
The concentration of DNA was measured using Nano drop and subjected to PCR amplification 
of the promoter regions of UCP1, Rb1, and PGC1α genes13. All the antibodies were obtained 
from Abcam and Millipore. Sybr Green master mix for qRT-PCR was purchased from Applied 
BioSystems, Foster City, CA and Stratagene Mx300P system (Stratagene, La Jolla, CA) were 
used to measure the gene expression pattern. The primers for PCR were obtained from Integrated 
DNA Technologies and the primer sequence are provided in Table 2. 
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Table 1: Primer sequence for TaqMan primer and probes 
Gene Sequence 
UCP1 FP: CACCTTCCCGCTGGACACT 
RP: CCCTAGGACACCTTTATACCTAATGG 
Probe: AGCCTGGCCTTCACCTTGGATCTGA 
PGC1α FP: CATTTGATGCACTGACAGATGGA 
RP: CCGTCAGGCATGGAGGAA 
Probe: CGTGACCACTGACAACGAGGCC 
PGC1β FP: AGGAAGCGGCGGGAAA 
RP: CTACAATCTCACCGAACACCTCAA 
Probe: AGAGATTTCGAATGTATACCACACGGCCTTCA 
COX-1 FP: TTTTCAGGCTTCACCCTAGATGA 
RP: GAAGAATGTTATGTTTACTCCTACGAATATG 
Probe: CATGAGCAAAAGCCCACTTCGCCA 
ACOX-1 FP: AAGAACTCCAGATAATTGGCACCTA or  
RP: AGTGGTTTCCAAGCCTCGAA 
Probe: CGGAGATGGGCCACGGAACTCAT  
or ATGAGTTCCGTGGCCCATCTCCG 
Cyclophilin FP: GGTGGAGAGCACCAAGACAGA 
RP: GCCGGAGTCGACAATGATG 
Probe: ATCCTTCAGTGGCTTGTCCCGGCT 
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Table 2: Primer sequence for ChIP analysis 
Gene Sequence 
UCP1 enhancer 
region 
FP: CTCCTCTACAGCGTCACAGAGG 
RP: AGTCTGAGGAAAGGGTTGA 
UCP1 start 
region 
FP: CCCACTAGCAGCTCTTTGGA 
RP: CTGTGGAGCAGCTCAAAGGT 
PGC1α Mef2 FP: GCTCGCTGCATTTCTTTCTT 
RP: CCCCACAGACTCAAAAACCA 
PGC1α CRE FP: CAAAGCTGGCTTCAGTCACA 
RP: AAAAGTAGGCTGGGCTGTCA 
Rb1 promoter 
region 
FP: TACTTGGGTTCGAGTCCTCTGCCAG 
RP: AGTTGGCCGTGTTCATGCG 
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4     RESULTS 
4.1 Role of pan HDAC inhibitors in brown adipose tissue gene regulation 
To examine how different HDACs regulate brown fat metabolism and function, we 
initially studied the effect of a pan HDAC inhibitor, TSA on H1B1B cell lines. The cells were 
pre-treated with TSA for 30 minutes followed by norepinephrine (adrenergic agonist) stimulation 
for 4 hours. After the treatment, a significant decrease of UCP1 expression was observed. Genes 
which are known to regulate of brown fat function such as: PPARγ, PRDM16 also showed a 
significant decrease. We also saw a decrease in RIP140, which is known as a negative regulator 
of UCP1 expression12 (Fig: 1A).  In contrast, we also observed a robust increase in PGC1α and 
PGC1β which are known as transcriptional co-actiavtors of UCP112. Acetyl Co-A oxidase-1 
(ACOX-1), which is involved in β-oxidation of fatty acids also showed a significant increase. 
Cell death- inducing DFFA- like effector a (CIDEA), which is postulated as a brown fat specific 
gene playing an important role in lipolysis and thermogenesis also increased after treatment with 
TSA 36 and 37 (Fig: 1B). SAHA, another pan inhibitor of HDACs showed similar effect to that of 
TSA and hence the rest of the experiments were continued with TSA as a pan inhibitor (Fig: 2). 
Similar results were observed for differentiated H1B1B cells when treated with TSA (Data not 
shown)
15 
 
Figure 1: Effect of TSA on H1B1B cells. 
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Figure 2: Effect of SAHA on H1B1B cells. 
 
4.2 Contrasting effect of Class-I and Class-II HDAC inhibition on UCP1 expression  
We next sought to identify how the specific classes of HDACs modulate gene expression 
profile in brown fat metabolism. For this, we pre-treated H1B1B cells with Class-I specific 
inhibitor, MS-275 and Class-II specific HDAC inhibitor, MC-1568 followed by norepinephrine 
stimulation. We observed a strikingly contrast effect on UCP1 expression. While Class-I HDAC 
inhibition showed a significant increase of UCP1 expression, opposite to that of the pan-HDAC 
16 
inhibitors, TSA and SAHA, the Class-II HDAC inhibition showed a significant decrease of 
UCP1, similar to that of TSA and SAHA (Fig: 3A and 3B). This contrasting effect of different 
HDACs suggests that different HDACs may regulate UCP1 gene expression in different ways. 
 
 
 
Figure 3: UCP1 expression in H1B1B cells. 
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4.3 Effects of Class-I HDAC inhibitor in brown adipocytes 
Similar to its effect on UCP1 expression, the treatment of Class-I HDAC inhibitor MS-
275 in H1B1B cells also promoted the gene expression of transcriptional activators of UCP1 
such as: PGC1α, PGC1β and PPARγ. It also increased the expression of ACOX-1 and CIDEA, 
which are associated with oxidation of fatty acids and lipolysis respectively (Fig: 4). These 
effects are similar to that of TSA in HIB1B cells. These data indicate that these HDAC inhibitors 
regulate the gene expression pattern differently.  
 
4.4 Role of HDAC inhibitors in BAT1 cell lines 
To confirm the effect of HDAC inhibition on brown adipocytes, a different brown fat cell 
line, BAT-1 were used. The studies were repeated by pre-treating the cell lines with HDAC 
inhibitors for 30 minutes and followed by isoproterenol (adrenergic stimulation) for 3 hours. As 
seen in H1B1B cell lines, BAT1 cells exhibited a similar gene expression profile after treatment 
with HDAC inhibitors. In addition to UCP1 down-regulation, TSA also decreased the gene 
expression of PPARγ, PRDM16 and classical brown fat markers like deiodenase-2 (DIO2), 
elongation of very long chain fatty acids (ELVOL3), potassium channel, subfamily K, member 3 
(KCNK3) and otopetrin 1 (OTOP1) (Fig: 5A and 5B). In contrast, TSA in BAT1 cells 
significantly up-regulated PGC1α, PGC1β and ACOX-1, similar to TSA’s effect on these gene 
expressions in HIB1B cells. 
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Figure 4: Effect of MS-275 in H1B1B cells. 
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Figure 5: Effect of TSA in BAT-1 cells. 
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Similar to H1B1B cell lines, BAT-1 cells also showed a significant decrease of UCP1 
expression after Class-II HDAC inhibition and increase of UCP1 after Class-I HDAC inhibition 
(Fig: 6A and 6B). 
 
 
Figure 6: UCP1 expression in BAT1 cells. 
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4.5 Increase in brown fat specific genes after Class-I HDAC inhibition 
Analogous to H1B1B cell lines, BAT-1 cells treated with Class-I HDAC inhibitor, MS-
275 showed a similar gene expression profile pattern. In BAT-1 cells, MS-275 increased the 
gene expression of PGC1α, COX-1, ACOX-1 and brown fat markers such as: ELVOL3 and 
DIO2 (Fig: 7). This suggests that inhibition of Class-I HDACs plays a crucial role in up-
regulation of brown fat gene expression whereas inhibition of Class-II HDACs significantly 
suppresses UCP1 expression in brown adipocytes. 
 
Figure 7: Effect of MS-275 in BAT1 cells. 
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To further investigate the effect of Class-I HDAC inhibitor in promotion of brown fat 
morphology, we treated white adipocytes at different time periods starting from 30 minutes to 4 
days. 3T3-L1 adipocytes, a classical white adipocyte cell line showed an increase in UCP1 
expression after treatment with MS-275 (Fig: 8).This clearly demonstrates the up-regulation of 
UCP1 expression by Class-I HDAC inhibition. 
 
 
Figure 8: Effect of MS-275 on UCP1 expression. 
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4.6 Class-II HDAC inhibitors target Rb1 to repress UCP1 expression: 
H1B1B and BAT-1 cell lines treated with TSA and MC-1568 showed a significant 
decrease of UCP1 expression and a robust increase of Rb1 expression. This suggests that TSA 
behaved more like a Class-II HDAC inhibitor in down-regulation of UCP1 expression and up-
regulation of Rb1 expression. In contrast, the Class-I HDAC inhibitor (MS-275) had a very 
minor or no significant effect on Rb1 expression (Fig: 9A and 9B). Since Rb1 is a negative 
regulator of UCP1 expression, we hypothesize that this robust increase of Rb1 expression by 
TSA and MC-1568 likely contributes to the inhibitory effects of TSA and MC-1568 on UCP1 
expression.  
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Figure 9: Rb1 expression after HDAC inhibitors treatment.
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4.7 Rb1 mediated epigenetic regulation of UCP1 expression by TSA and MC-1568. 
TSA inhibits HDACs, which in turn increases the acetylation levels on histone lysine 
sites47. We assessed the changes in histone acetylation status of Rb1 promoter region. Using 
ChIP analysis, we studied the histone acetylation pattern of H3K27 residues on Rb1 promoter in 
BAT-1 cells after treatment with TSA and MC-1568.  Treatment with TSA and MC-1568 
enriched acetylated H3K27at the promoter region of Rb1, which may in turn, be responsible for 
the increased Rb1 expression observed after TSA and MC-1568 treatment. This increased 
expression of Rb1 may then inhibit UCP1 expression17. This demonstrates how the treatment 
with Class-II HDAC inhibitor suppressed UCP1 expression by recruiting more acetylated histone 
groups on repressor genes, such as Rb1 promoter regions and thus promoting its gene expression 
(Fig: 10). 
 
In line with ChIP results, to confirm that increase in Rb1 expression is responsible for 
suppression of UCP1 expression, we performed siRNA knockdown of Rb1 in brown adipocytes. 
After siRNA knockdown, Rb1 expression was decreased by 70% (Fig: 11A). After knockdown 
of Rb1, UCP1 expression was significantly increased at both basal level and isoproterenol 
treatment level (Fig: 11B). In addition, Rb1 knock down completely reversed the effect of TSA 
on inhibiting UCP1 expression when treated with isoproterenol. Rb1 knockdown also reversed 
the effect of MC-1568 on inhibiting UCP1 expression both at the basal level and isoproterenol 
stimulated condition.  
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Figure 10: Effect of HDACs on Rb1 promoter region. 
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Figure 11: Effect of Rb1 knockdown in UCP1 expression. 
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4.8 Mechanism of Class-I HDAC inhibition 
There are evidence from literature that, PGC1α is important in up-regulation of UCP1 
expression2, 12, and 25. To explore the mechanism of Class-I HDAC inhibition in the up-regulation 
of UCP1 expression, we treated cells with MS-275 and performed ChIP assay to study the 
acetylation status of PGC1α transcriptional regions: Mef2 (Myocyte enhancer factor) and CREB 
(cAMP response element blinding region) binding sites. The CREB- and Mef2-binding sites are 
two important cis-elements on PGC1α promoter that transactivate its expression25, 26, and 27. Our 
results indicate a significant recruitment of acetyl groups to both CREB and Mefs sites, with 
CREB-binding site showing the most significant increase in acetylation status over Mef binding 
region (Fig: 12A). In addition, MS-275 also promoted acetylation of H3 residues on UCP1 start 
and enhancer regions with UCP1-start region showing the most significant effect over the UCP1-
enhancer region40 (Fig: 12B). 
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Figure 12: ChIP analysis after MS-275 treatment. 
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The role of PGC1α in mediating the effect of MS-275 in UCP1 expression is verified by 
siRNA knockdown of PGC1α. The knockdown efficiency was more than 70% and it 
significantly reduced UCP1 expression both at basal level and isoproterenol treatment level. It 
also significantly prevented the increase in UCP1 expression after treating the cells with the 
compound, MS-275. This suggests that (i) PGC1α is very important for regulating UCP1 
expression (ii) PGC1α is mediating MS-275 effect on up-regulating UCP1 expression (Fig: 13).  
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Figure 13: Role of PGC1α knockdown in UCP1 expression. 
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5  DISCUSSION 
It is long known that sympathetic activation is important for UCP1 expression. For 
example: the activation of β3 adrenergic receptor can up-regulate the protein kinase A (PKA) 
signaling pathway, which promotes UCP1 gene expression43, 44. In addition, there are important 
transcriptional regulators of UCP1 such as: PGC1α, PGC1β, and PRDM16, which are known to 
regulate UCP1 expression. Thus, over expression of PGC1α or PRDM16 can also promote 
UCP1 expression 45, 46. There are evidences that support modification in histone acetylation 
pattern and other epigenetic modifications like DNA methylation can also up-regulate UCP1 
expression 6,7,10. However, in spite of the large amount of informations available towards the 
regulation of brown fat function by these signaling pathways and transcriptional regulators, 
specific information on epigenetic regulation of brown fat metabolism remains unclear. A recent 
study on Class-I HDACs revealed its role on oxidative metabolism in skeletal muscle10. Other 
previous studies on butyrate, which blocks HDAC function have also reported a positive role of 
HDAC inhibition in energy expenditure 28, 29 and 30. These well-established studies provide 
evidence that, HDACs play an important role in energy metabolism. 
 
However the detailed mechanisms of how histone acetylation regulate UCP1 expression 
is unclear. Through our study, we have addressed this question by providing a direct evidence for 
the mechanism of UCP1 regulation after HDAC inhibition.  Although literature provides us with 
some insight about the role of Class-I HDACs in adipocytes and myocytes10, the exact 
mechanism is still unknown. In addition, the effect of Class-II HDAC in the regulation of UCP1 
expression is unclear.  
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In our study, we used a pan HDAC inhibitor-TSA, Class-I HDAC inhibitor-MS-275 and 
Class-II HDAC inhibitor- MC-1568 on various adipocyte cell lines to understand the molecular 
basis and epigenetic mechanisms of the regulation of UCP1 expression by different HDACs. Our 
efforts were focused on identifying both the activators and repressors of UCP1 induced by 
epigenetic modulation by HDACs. 
 
Our results show that TSA, a pan inhibitor of HDACs, and MC-1568, a class II HDAC 
inhibitor, significantly down-regulated UCP1 expression, whereas MS-275, a class I HDAC 
inhibitor, significantly up-regulated UCP1 expression. In addition, while TSA behaves more like 
a class II HDAC inhibitor in inhibiting UCP1 expression, TSA up-regulates PGC1α expression, 
similar to that of the class I HDAC inhibitor, MS-275. These data suggest that different HDACs 
may exert different effects regulating brown fat gene expression.  
 
Treatment with MS-275 inhibits the Class-I HDACs and our data suggests that it 
increases UCP1 expression in brown adipocyte cell lines (Fig: 3 and 6). This increase in UCP1 
expression is correlated with increase in its activator: PGC1α (Fig: 4 and 7).  To further evaluate 
the role of MS-275 in up-regulation of PGC1α, we performed ChIP on PGC1α. Previously 
identified transcriptional enhancer regions of PGC1α: Mef and CRE sites were targeted for our 
ChIP expereiemnts10, 25, 26 and 27. Our results on inhibition of Class-I HDACs by MS-275 showed 
increased acetylation on both the sites and a more significant effect was seen at the CRE site 
(Fig: 12A).  This enrichment of histone acetylation at PGC1α transcription region, after 
treatment with MS-275 is consistent with the previous work done by Galmozzi et al10.  
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In our study, we have also shown that MS-275 can directly promote acetylation at the 
UCP1 transcriptional regulatory and start region. From previous established data, we know that 
UCP1 transcriptional regulatory region is present around 2.8 kb from its start site38 and 39. This 
region includes binding motifs like: CRE, PPRE (peroxisomal proliferator activator receptor 
binding motif), BRE (brown adipocyte regulatory element) and also some negative regulatory 
elements, such as Rip-140 binding site.  Our results indicate that MS-275 can enrich histone 
acetylation at this UCP1 enhancer region, as well as at the UCP1 transcriptional start region (Fig: 
12B). We believe, MS-275 can directly act on UCP1 and as well act on UCP1 positive regulator, 
PGC1α to up-regulate its expression.  Apart from this, MS-275 also increased a whole panel of 
brown fat specific genes and thus promoting brown adipocyte function (Fig: 4 and 7). Not only 
in brown adipocyte cell line, but also in white adipocyte cell line, MS-275 significantly up-
regulated UCP1 expression (Fig: 8), indicating that MS-275, by inhibiting Class-I HDACs, may 
also be important in the browning of white adipocytes. This compound, MS-275 in animal model 
showed a physiological significance in ameliorating obesity and promoted up-regulation of 
PGC1α in skeletal muscles in other studies 10. Based on all of these evidences and our results, we 
interpret that inhibition of Class-I HDACs play a vital role in enhancing brown adipocyte 
function, and in browning of white adipocytes and thus induction of beige cell phenotype in 
white adipocytes.  
 
To confirm that treatment with MS-275, exerted its effect on UCP1 by directly targeting 
PGC1α, we performed knockdown of PGC1α in brown adipocytes.. After knockdown, we 
observed that effect of MS-275 on UCP1 up-regulation was significantly reversed. Thus, the 
inhibition of Class-I HDACs increased the acetylation status of PGC1α and as well as increased 
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the acetylation status of both UCP1 start and enhancer region. Taken together, these epigenetic 
changes significantly up-regulate UCP1 expression. 
 
On the other hand, both TSA and Class-II HDAC inhibitor, MC-1568 significantly down-
regulated UCP1 expression. We hypothesize, the inhibition of HDACs by TSA and MC-1568 
activate certain repressor genes that are responsible for the suppression of UCP1 expression. 
From literature, we know that Rb1 and RIP140 are well documented negative regulators of 
UCP1 11, 12, 17 and 18. Our results indicate that all the HDAC inhibitors used in our study: TSA, 
MS-275 and MC-1568 up-regulated RIP140. Whereas only MC-1568 and TSA up-regulated 
Rb1,while  MS-275 had no effect on Rb1 expression (Fig: 9). Based on this result, we expect 
Rb1 to be a likely target for Class-II HDAC inhibitors to down-regulate UCP1 expression. 
Therefore, we focused the rest of our experiments on Rb1.  
 
 Rb1, which is primarily known as a tumor suppressor gene, is also known to regulate 
apoptosis, cell proliferation and differentiation 31-33. In rodents, Rb1 is known as a negative 
regulator of brown adipocyte differentiation34. The inactivation of Rb1 is thought to induce 
brown fat like features in white adipocytes. In literature, however there is no clear evidence how 
Rb1 gene expression can be regulated by epigenetic mechanisms, which in turn controls UCP1 
expression.  
 
Our ChIP results clearly demonstrated that inhibiting Class-II HDACs recruited more 
acetyl groups on Rb1 promoter region which may in turn up-regulate its expression (Fig: 10). 
This indicates that inhibition of Class-II HDACs promoted Rb1 gene expression and Rb1 being a 
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negative regulator of UCP1, can suppresses UCP1 expression by negatively regulating PKA-
CREB pathway17. 
 
 The increase in Rb1 expression can indirectly inhibit up-regulation of UCP1 expression 
by inhibiting the PKA signaling cascade. PKA signaling cascade can be activated by sympathetic 
stimulation. When adrenergic agonists, such as norepinephrine and isoproterenol bind to their G-
Protein Coupled Receptor (Gs), the Gα subunit is released to activate adenylate cyclase (AC). AC 
can catalyze the generation of cAMP, which binds to PKA to release the regulatory subunit from 
the catalytic site. The free, activated PKA catalytic unit can now diffuse inside the nucleus to 
phosphorylate and activate cAMP Response Element Binding Protein (CREB). The activated 
CREB can act on its downstream target or the promoter regions of various genes to up-regulate 
their expression. For example, CREB binds directly to UCP1 promoter to activate its gene 
expression38 and 39.  
 
From literature, we know that transcription of Protein Kinase A can be differentially 
regulated by either up-regulating the synthesis of regulatory subunits or its catalytic subunit35. 
Cell utilizes this function to regulate the PKA signaling cascade. Rb1 increases FOXC2 
(Forkhead box protein C2), which is a transcription factor belonging to FOX (Forkhead box) 
family. This FOXC2 can then increase PKA-RIα (Protein Kinase A- Regulatory Subunit-Iα) 
expression, which is a negative regulator of PKA signaling cascade. Thus up-regulation of Rb1 
expression via enriched histone acetylation on its promoter can in turn increase the PKA-RIα 
subunit. This can suppress UCP1 expression by inhibiting the PKA signaling pathway (Fig 14). 
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This is indeed consistent with literature that up-regulation of Rb1 increases PKA-RIα, which 
inhibits the upstream signaling of β-agonist to decrease PKA activity17.  
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Figure 14: A cartoon depicting the mechanism of different mode of action by different HDAC inhibitors. 
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The following evidences support our hypothesis that Rb1 mediates the effect of Class-II 
HDAC inhibitors in suppression of UCP1 expression: i) significant increase in Rb1 expression 
after TSA and MC-1568 treatment, which is consistent with significant decrease in UCP1 
expression ii) enrichment of H3K27 acetylation at Rb1 promoter region to up-regulate its 
expression iii) the ability of Rb1 knockdown to reverse the effect of TSA and MC-1568 in 
suppression of UCP1. In summary, all these data clearly demonstrates that Rb1 mediates 
suppression of UCP1 expression by TSA and MC-1568 in brown adipocytes. To our knowledge, 
this is the first study which links the epigenetic modulation of Rb1 in regulation of UCP1 
expression. 
 
In conclusion, we believe that there exists two different regulatory mechanism of UCP1 
expression. Class-I HDAC inhibition can up-regulate UCP1 expression through PGC1α and 
Class-II HDAC inhibition can down-regulate UCP1 expression through Rb1. To the best of our 
knowledge this is the first study which links the epigenetic regulation of UCP1 via HDAC 
inhibition.  
 
In spite of understanding the mechanism of Class-I and Class-II HDACs on UCP1 
expression, the role of specific HDACs in regulation of UCP1 is yet to be studied. This will 
further help us understand how epigenetics control brown fat thermogenesis and what role it 
plays in energy balance. By targeting the specific HDACs using synthetic or natural drugs, it 
might be possible to develop a promising therapy towards treatment of obesity and its associated 
disorders. 
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